Adrenal Incidentaloma and Phaeochromocytoma for the Surgeon — Image by Density, Block the Catecholamines, Resect by Biology

The adrenal incidentaloma wants three verdicts before the knife — whose imaging is truly benign, whose hormones earn an operation, and whose catecholamines or cancer biology dictate the approach — because density exempts testing only at 10 HU, washout mimics phaeochromocytoma in nearly one-third, and Conn cures biochemistry far more often than blood pressure. Work every mass up with metanephrines and a 1-mg dexamethasone test, block phaeochromocytoma per the split-endpoint trials, resect Conn for biochemical cure with honest blood-pressure counselling, weigh MACS surgery by comorbidity, clear ACC en bloc with nodes, and choose laparoscopy for benign disease with open caution for cancer — with every number taken from the papers named beside it.^{[1][18][12][9][2]}

A 52-year-old woman has a 2.8 cm lipid-poor adrenal nodule; a 41-year-old man sweats through hypertensive paroxysms with raised metanephrines; and a 58-year-old man has drug-resistant hypertension with lateralising aldosteronism. One needs imaging verdicts without over-testing, one needs blockade arithmetic before laparoscopy, and one needs cure counselling before adrenalectomy. The examiner will watch you quote HU 10 against washout mimics, apply the dexamethasone cutoff with MACS logic, defend blockade choice with PRESCRIPT splits and cost trends, price Conn success with PASO predictors, grade ACC surgery with lymphadenectomy and ADIUVO numbers, and concede the lap-versus-open cancer equipoise — with every number taken from the papers named beside it.^{[1][2][12][10][19]}

Incidentaloma is a scan finding, not a disease: adrenal masses detected on imaging performed for reasons other than suspected adrenal disease, most often nonfunctioning adenomas but hiding carcinoma, phaeochromocytoma, hormone-producing adenoma or metastases underneath.^[1] Discovery has shifted surgical practice — modern phaeochromocytomas surface most often as incidental cross-sectional findings at 61% against 27% symptomatic and 12% mutation-detected, with incidental tumours older, smaller and less blockade-hungry than symptomatic ones.^[23] The strategic arc fits one sentence: exempt only the dense-benign on imaging, test every other lesion hormonally, operate for malignancy risk or hormone excess with age and fitness in the balance, block catecholamines by trial arithmetic, and stage cancer surgery en bloc with nodes.^{[1][9][2][11]}

Density rules imaging: homogeneous lesions at HU 10 or less on unenhanced CT are benign and need no further imaging whatever their size, while only inhomogeneous lesions above 4 cm with HU above 20 carry malignancy risk high enough that surgery is the usual answer — everything between goes to multidisciplinary discussion.^[1] Washout rules in benignity but never rules out phaeochromocytoma: benignity at 100% positive predictive value needs 30 mm with 20 HU, 40 mm with 15 HU, relative washout above 53% or absolute washout above 78%, with classical 60% absolute and 40% relative thresholds safe only when metanephrines are normal.^[16] Lipid-poor washout is a rule-in test: at 60% absolute washout or above, 92.2% are adenomas yet 6.9% are phaeochromocytomas, with overall sensitivity 67.6%, specificity 77.8% and accuracy 69.7% — so a washing lesion with even mild metanephrine elevation stays suspicious.^[17] Phaeochromocytoma hides in washout: 99.5% exceed 10 HU so HU 10 or less reasonably exempts biochemical testing, but 28.9% of washout-studied phaeochromocytomas show adenoma-like absolute or relative washout — washout cannot exclude it.^[18]

Every patient gets the same hormonal screen: plasma or urinary metanephrines plus a 1-mg overnight dexamethasone suppression test at a cortisol cutoff of 50 nmol/L (1.8 µg/dL) or less.^[1] Above that cutoff without overt Cushing features is mild autonomous cortisol secretion — MACS — carrying excess morbidity and mortality risk, screened for cortisol-attributable hypertension and diabetes, and considered for surgery in individualised fashion when relevant comorbidities coexist.^[1] Surgical fitness is five-factor: likelihood of malignancy, presence and degree of hormone excess, age, general health and patient preference.^[1]

Conn surgery cures chemistry more than pressure: across 705 adrenalectomies for lateralised disease, complete clinical success reached only 37% with another 47% partial, while complete biochemical success reached 94% — most patients benefit, few leave drugs behind.^[12] Youth and female sex predict drug freedom: women carry 2.25-fold odds of complete clinical success and 2.89-fold odds of any clinical benefit, each extra year of age trims odds by 5%, and each extra preoperative drug unit trims complete-success odds by 20%.^[12] The single-centre picture agrees: 87 Conn adrenalectomies halved drug load from 5.4 to 3.0 defined daily doses with only 22% fully drug-free, yet 87% gained better hypertension control — female sex and fewer than 4 baseline drug doses predicting cure.^[13] Counsel accordingly: operate lateralised Conn for near-certain biochemical cure with probable but partial pressure gain, and screen every Endocrine Society-criteria patient because biochemical cure matters even when drugs continue.^[12]

Subclinical Cushing rewards resection on comorbidity: 117 adrenalectomies improved blood pressure, cholesterol, body mass index and diabetic control with fewer prescribed drugs, the largest drug reductions clustering at post-dexamethasone cortisol between 1.8 and 3.0 µg/dL — the test result predicts the benefit.^[14] Meta-analysis agrees against conservatism: adrenalectomy improved hypertension in 61%, diabetes in 52%, obesity in 45% and dyslipidaemia in 24%, beating conservative management on hypertension elevenfold and diabetes nearly fourfold, though dyslipidaemia and obesity gains miss significance.^[15]

Blockade starts two to three weeks before surgery — and PRESCRIPT splits its verdict: across 134 nonmetastatic PPGL patients titrated to blood-pressure targets, cumulative time outside target was 11.1% on phenoxybenzamine against 12.2% on doxazosin with no difference, while the instability score favoured phenoxybenzamine at 38.0 against 50.0 — better stability without proven better clinical outcome, and 30-day cardiovascular complications tied at 8.8% against 6.9% with no deaths.^[2] Calcium-channel blockade has pilot-RCT support: amlodipine to 20 mg daily against prazosin GITS to 30 mg daily cut hypertensive episodes from a median 2 to 0, hypertension duration from 19 to 0 minutes and instability time from 22.85% to 2.44% with hypotension tied and no mortality — efficacious, awaiting larger trials against phenoxybenzamine or doxazosin.^[3] Selectivity trades hypotension for support: selective blockade brings systolic below 80 in 67% against 35% on phenoxybenzamine with no overall intraoperative difference, but more postoperative vasopressor or intensive-care need — safe either way, with selective cases needing more rescue.^[4] Practice has already moved: phenoxybenzamine first-line use fell from 71.0% in 2008 to 21.2% in 2019 as selective blockers rose from 6.5% to 42.4%, driven by cost from $722 to $9,616 per course — with stay and perioperative costs tied.^[5] Doxazosin at 2 to 16 mg daily matches phenoxybenzamine on pressure and rate with fewer side effects, and its blockade washes out by postoperative day one while phenoxybenzamine persists beyond two days — with urinary norepinephrine guiding the daily requirement in noradrenergic tumours.^[26] Nicardipine matches phenoxybenzamine across pre-, intra- and postoperative stability especially below 3 cm, and magnesium infusion adds no measurable stability in that series.^[25] The no-blockade challenge is honest but nonrandomised: fifteen nonrandomised studies in 3,542 patients find no intraoperative or cardiovascular difference with blockade, but prolonged hypotension and vasopressor use quadruple with it — equipoise stated, randomised proof still owed.^[20]

Size and approach predict the storm: each centimetre of tumour raises severe hypertensive episodes 1.40-fold and postoperative vasopressor odds 1.23-fold, while open adrenalectomy and selective blockade multiply systolic-over-200 episodes 27.8-fold and 20.9-fold respectively — with open surgery adding readmissions, complications, vasopressors and 4.6 extra days.^[7] Two decades confirm the discipline: morbidity and mortality fell significantly in the later decade as phenoxybenzamine dosing rose from 59 to 106 mg and laparoscopy doubled from 27% to 54%, with higher blockade dose predicting stability and magnesium use blunting pressure-driven instability.^[6] Crisis is treatable but undefined: catecholamine crises at 180/120 mmHg or above complicate into tachyarrhythmia, hypotension or organ damage, diagnosed past confounders and managed by available drugs with endocrinology-cardiology co-care.^[22] Presentation is paroxysmal: headaches, sweating, palpitations with hypertension from secreted catecholamines, tested biochemically in symptomatic, incidentaloma and predisposed patients, localised by CT or MRI with MIBG, then removed laparoscopically after blockade — excellent prognosis when timely, poor when metastatic, especially large and extra-adrenal.^[21] Symptomatic tumours declare themselves chemically: highest metanephrine concentrations and the heaviest blockade need at median 450 mg phenoxybenzamine against 375 mg incidental and 270 mg mutation-detected.^[23]

Pathology scores the follow-up: the PASS system weights invasion, nested and diffuse growth, necrosis, cellularity, spindling, monotony, mitoses above 3 per 10 high-power fields with atypical forms, pleomorphism and hyperchromasia — 4 or more flagging aggressive potential against benign behaviour below 4 across 100 tumours averaging 7.2 cm.^[8]

ACC surgery is en bloc by experts: every suspected case needs endocrine workup with adrenal-focused imaging and multidisciplinary discussion, resection only by adrenal-oncology surgeons aiming at complete en-bloc clearance including oligo-metastatic disease, Weiss and Ki67 pathology review, and no routine surgery in widespread metastases — mitotane with or without etoposide, doxorubicin and cisplatin instead, operating later only on response.^[9] Nodes matter: among 283 German-registry resections, only 16.6% had intended lymphadenectomy, yet adjusted analysis cut recurrence hazard to 0.65 and disease-death hazard to 0.54 — dissect locoregional nodes for staging and outcome.^[11] Mitotane after low-grade resection is restraint, not reflex: ADIUVO randomised 45 to mitotane at 14 to 20 mg/L plasma target for two years against 46 to surveillance in R0 stage I to III disease with Ki67 10% or less — five-year recurrence-free survival 79% against 75% with hazard 0.74 and no significance, survival 95% against 86% likewise tied, every treated patient suffering adverse events with 19% discontinuing and no grade 4 events or treatment deaths.^[10] Approach for ACC is contested — report both sides: thirteen studies in 1,171 ENSAT I to III patients find laparoscopy equivalent to open on R0 rate, recurrence, disease-free and overall survival with smaller tumours, shorter operations, less bleeding and briefer stays — extent of resection, not route, dictating outcome.^[24] Against that, the state-of-art review keeps open surgery as the keystone wherever neighbours, organs or vessels are involved and warns that laparoscopy for localised ACC brings higher local and peritoneal recurrence with shorter recurrence-free survival.^[19] Default discipline: laparoscopy — transperitoneal or retroperitoneal — first for small-to-medium benign lesions and feasible even when larger without malignant signs, robotics comparable, open reserved for cancer.^[19]

References26ShowHide

1. [1]Fassnacht M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol, 2023.PMID 37318239
2. [2]Buitenwerf E, et al. Efficacy of α-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial. J Clin Endocrinol Metab, 2020.PMID 31714582
3. [3]Jaiswal SK, et al. Preoperative Amlodipine Is Efficacious in Preventing Intraoperative HDI in Pheochromocytoma: Pilot RCT. J Clin Endocrinol Metab, 2021.PMID 33839787
4. [4]Randle RW, et al. Selective Versus Non-selective α-Blockade Prior to Laparoscopic Adrenalectomy for Pheochromocytoma. Ann Surg Oncol, 2017.PMID 27561909
5. [5]Kuo EJ, et al. Phenoxybenzamine is no longer the standard agent used for alpha blockade before adrenalectomy for pheochromocytoma: A national study of 552 patients. Surgery, 2023.PMID 36167697
6. [6]Livingstone M, et al. Hemodynamic Stability During Pheochromocytoma Resection: Lessons Learned Over the Last Two Decades. Ann Surg Oncol, 2015.PMID 25822781
7. [7]Kiernan CM, et al. Predictors of hemodynamic instability during surgery for pheochromocytoma. Ann Surg Oncol, 2014.PMID 24939623
8. [8]Thompson LD, et al. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol, 2002.PMID 11979086
9. [9]Fassnacht M, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol, 2018.PMID 30299884
10. [10]Terzolo M, et al. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. Lancet Diabetes Endocrinol, 2023.PMID 37619579
11. [11]Reibetanz J, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg, 2012.PMID 22143204
12. [12]Williams TA, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol, 2017.PMID 28576687
13. [13]Hartmann I, et al. Hypertension outcomes of adrenalectomy for unilateral primary aldosteronism. Endocrine, 2022.PMID 35147923
14. [14]Sato H, et al. Adrenalectomy in Japanese patients with subclinical Cushing syndrome: 1-mg dexamethasone suppression test to predict the surgical benefit. Int J Urol, 2021.PMID 33258172
15. [15]Bancos I, et al. THERAPY OF ENDOCRINE DISEASE: Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing's syndrome: a systematic review and meta-analysis. Eur J Endocrinol, 2016.PMID 27450696
16. [16]Marty M, et al. Diagnostic accuracy of computed tomography to identify adenomas among adrenal incidentalomas in an endocrinological population. Eur J Endocrinol, 2018.PMID 29467231
17. [17]Akbulut S, et al. A Critical Analysis of Computed Tomography Washout in Lipid-Poor Adrenal Incidentalomas. Ann Surg Oncol, 2021.PMID 33210268
18. [18]Canu L, et al. CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. J Clin Endocrinol Metab, 2019.PMID 30383267
19. [19]Fiori C, et al. Adrenal tumours: open surgery versus minimally invasive surgery. Curr Opin Oncol, 2020.PMID 31644473
20. [20]Wang J, et al. Preoperative α-blockade versus no blockade for pheochromocytoma-paraganglioma patients undergoing surgery: a systematic review and updated meta-analysis. Int J Surg, 2023.PMID 37037514
21. [21]Lenders JW, et al. Phaeochromocytoma. Lancet, 2005.PMID 16112304
22. [22]Nazari MA, et al. Catecholamine-induced hypertensive crises: current insights and management. Lancet Diabetes Endocrinol, 2023.PMID 37944546
23. [23]Gruber LM, et al. Pheochromocytoma Characteristics and Behavior Differ Depending on Method of Discovery. J Clin Endocrinol Metab, 2019.PMID 30462226
24. [24]Mpaili E, et al. Laparoscopic Versus Open Adrenalectomy for Localized/Locally Advanced Primary Adrenocortical Carcinoma (ENSAT I-III) in Adults: Is Margin-Free Resection the Key Surgical Factor that Dictates Outcome? A Review of the Literature. J Laparoendosc Adv Surg Tech A, 2018.PMID 29319399
25. [25]Siddiqi HK, et al. Utility of oral nicardipine and magnesium sulfate infusion during preparation and resection of pheochromocytomas. Surgery, 2012.PMID 23158177
26. [26]Prys-Roberts C, et al. Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J Surg, 2002.PMID 12192533